BIAF
bioAffinity Technologies, Inc.1.3800
-0.1000-6.76%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
6.21MP/E (TTM)
-Basic EPS (TTM)
-13.83Dividend Yield
0%Recent Filings
8-K
8-K
8-K
8-K
Validates CyPath Lung protocols
bioAffinity Technologies announced on October 20, 2025, a presentation at CHEST 2025 validating sputum storage and shipping protocols for its CyPath Lung test, which detects early-stage lung cancer with 92% sensitivity and 87% specificity in high-risk patients. The research, presented by Dr. Rossella Titone on October 22, underscores reliable home sample collection yielding results in two days. This bolsters CyPath Lung's noninvasive edge. Yet risks could alter outcomes.
8-K
Regains Nasdaq compliance
bioAffinity Technologies regained Nasdaq compliance on October 14, 2025, meeting the $1.00 minimum bid price and $2.5 million stockholders' equity rules after a hearings panel review. This secures continued trading of its common stock and warrants on the Nasdaq Capital Market. Yet a one-year mandatory monitor looms. Noncompliance with equity standards during monitoring triggers delisting risks without extra time.
IPO
Employees
Sector
Industry
BDSX
Biodesix, Inc.
7.90+0.38
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
CHEK
Check-Cap Ltd.
1.61+0.03
GNTLF
GENETIC TECHNOLOGIES
1.00+0.00
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
LH
Labcorp Holdings Inc.
258.11-5.22
PRPO
Precipio, Inc.
24.02-0.04
TECH
Bio-Techne Corp
57.44-1.25
VCYT
Veracyte, Inc.
43.22-0.31